Cargando…
2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade
BACKGROUND: Urinary tract infection (UTI) is one of the most common infectious diagnoses and in 2007 accounted for 10.5 million primary care visits in the US Advancing age and comorbidities, such as chronic kidney disease (CKD) and diabetes, affect antimicrobial prescribing habits. Sulfamethoxazole/...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254762/ http://dx.doi.org/10.1093/ofid/ofy210.2045 |
_version_ | 1783373799418232832 |
---|---|
author | Kraitman, Natan Fredenrich, Jaela DeLucca, Brandon Toney, John |
author_facet | Kraitman, Natan Fredenrich, Jaela DeLucca, Brandon Toney, John |
author_sort | Kraitman, Natan |
collection | PubMed |
description | BACKGROUND: Urinary tract infection (UTI) is one of the most common infectious diagnoses and in 2007 accounted for 10.5 million primary care visits in the US Advancing age and comorbidities, such as chronic kidney disease (CKD) and diabetes, affect antimicrobial prescribing habits. Sulfamethoxazole/trimethoprim (SMX-TMP), nitrofurantoin, and fosfomycin are first-line recommendations for uncomplicated cystitis. In an aging male population with potential allergies or contraindications to the above, fosfomycin is a potential option for treatment. METHODS: A retrospective chart review of fosfomycin prescribing habits at a large VA academic medical center. Patients were selected based on fosfomycin prescription in both inpatient and outpatient settings from January 1, 2004 to December 5, 2017. Data reviewed included indication, organism(s), susceptibility, duration of treatment, CKD, and clinical success. Treatment success was defined as no representation with UTI symptoms for 30 days. RESULTS: 117 cases of UTI in which fosfomycin was used were identified with a median patient age of 70 years old and 90% male. Twenty-five were uncomplicated cystitis, 49 complicated cystitis, and 34 catheter associated infections. Treatment success was obtained in 92% of the uncomplicated cystitis cases, 76% in complicated cystitis cases, and 67% in catheter associated UTIs. In half of all the cases an ESBL bacterium was isolated and 79% were successfully treated with fosfomycin. The most common pathogen identified was E. coli 58/118 (49%), followed by Klebsiella 25/118 (21%). CONCLUSION: Fosfomycin is an antibiotic recommended for simple cystitis due to its safety profile, less collateral damage (gut flora disturbance), and low resistance as currently known. This review displays the largest ESBL cohort identified in the literature and uniquely used in a predominant male population. These findings suggest that ESBL producing bacteria can be treated successfully with fosfomycin in a male population as well as uncomplicated cystitis. However, caution should be used with catheterized patients as treatment was less effective regardless of isolated bacteria. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6254762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62547622018-11-28 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade Kraitman, Natan Fredenrich, Jaela DeLucca, Brandon Toney, John Open Forum Infect Dis Abstracts BACKGROUND: Urinary tract infection (UTI) is one of the most common infectious diagnoses and in 2007 accounted for 10.5 million primary care visits in the US Advancing age and comorbidities, such as chronic kidney disease (CKD) and diabetes, affect antimicrobial prescribing habits. Sulfamethoxazole/trimethoprim (SMX-TMP), nitrofurantoin, and fosfomycin are first-line recommendations for uncomplicated cystitis. In an aging male population with potential allergies or contraindications to the above, fosfomycin is a potential option for treatment. METHODS: A retrospective chart review of fosfomycin prescribing habits at a large VA academic medical center. Patients were selected based on fosfomycin prescription in both inpatient and outpatient settings from January 1, 2004 to December 5, 2017. Data reviewed included indication, organism(s), susceptibility, duration of treatment, CKD, and clinical success. Treatment success was defined as no representation with UTI symptoms for 30 days. RESULTS: 117 cases of UTI in which fosfomycin was used were identified with a median patient age of 70 years old and 90% male. Twenty-five were uncomplicated cystitis, 49 complicated cystitis, and 34 catheter associated infections. Treatment success was obtained in 92% of the uncomplicated cystitis cases, 76% in complicated cystitis cases, and 67% in catheter associated UTIs. In half of all the cases an ESBL bacterium was isolated and 79% were successfully treated with fosfomycin. The most common pathogen identified was E. coli 58/118 (49%), followed by Klebsiella 25/118 (21%). CONCLUSION: Fosfomycin is an antibiotic recommended for simple cystitis due to its safety profile, less collateral damage (gut flora disturbance), and low resistance as currently known. This review displays the largest ESBL cohort identified in the literature and uniquely used in a predominant male population. These findings suggest that ESBL producing bacteria can be treated successfully with fosfomycin in a male population as well as uncomplicated cystitis. However, caution should be used with catheterized patients as treatment was less effective regardless of isolated bacteria. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254762/ http://dx.doi.org/10.1093/ofid/ofy210.2045 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Kraitman, Natan Fredenrich, Jaela DeLucca, Brandon Toney, John 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title | 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title_full | 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title_fullStr | 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title_full_unstemmed | 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title_short | 2392. Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade |
title_sort | 2392. fosfomycin utilization and outcomes in a large va medical center over a decade |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254762/ http://dx.doi.org/10.1093/ofid/ofy210.2045 |
work_keys_str_mv | AT kraitmannatan 2392fosfomycinutilizationandoutcomesinalargevamedicalcenteroveradecade AT fredenrichjaela 2392fosfomycinutilizationandoutcomesinalargevamedicalcenteroveradecade AT deluccabrandon 2392fosfomycinutilizationandoutcomesinalargevamedicalcenteroveradecade AT toneyjohn 2392fosfomycinutilizationandoutcomesinalargevamedicalcenteroveradecade |